NasdaqGS:LEGNBiotechs
Legend Biotech (LEGN) Valuation Check After Strong Revenue Growth And Narrowing Quarterly Loss
Legend Biotech’s Earnings Spark Fresh Interest in the Stock
Legend Biotech (LEGN) recently released first quarter 2026 results, reporting revenue of US$305.1 million and a net loss of US$54.3 million. This compares with revenue of US$195 million and a net loss of US$101 million a year earlier.
See our latest analysis for Legend Biotech.
Legend Biotech’s 1 day share price return of 10.48% came alongside the earnings release, while the 30 day share price return of 55.62% suggests momentum has...